By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?
GeopolíticaOne-OffSaúde e medicina3a
Manifold MarketsSem KYCDados de resolução verificadosRazoavelmente calibradoAviso de qualidade dos dadosDados da fonte degradados
Dados de 26 de out. de 2026, 06:50 UTC · política pm-quality-4
Previsão da comunidade atualSim 53.5%
Previsores
5
Tipo de pergunta
binary
Metodologia
Play-money forecasting platform
Tipo de fonte
Previsão
Dados do mercado
Atualizado há 2 horas
Desatualizado18/11/22, 02:41 UTC1/01/30, 08:00 UTC
Tendências
Regras
Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system.
- There's a list of major immune checkpoint inhibitors here: https://en.wikipedia.org/wiki/Checkpoint_inhibitor
- A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless.
- You can read an overview of the topic here: https://sci-hub.se/10.1093/annonc/mdw217
- This market resolves YES if any combination therapy is approved that:
- Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.
